Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Heise

Showing results (51-60 of 150) with videos related to

Pageof 15
Sort By:
The Journal of Clinical Endocrinology and Metabolism|April 16, 2013
Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitusDavid Polidori, Sue Sha, Atalanta Ghosh, et al.
Journal of Diabetes Science and Technology|October 16, 2013
A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trialAndreas Liebl, Jaime Davidson, Henriette Mersebach, et al.
Expert Opinion on Drug Metabolism & Toxicology|June 19, 2015
Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargineTim Heise, Ulrike Hövelmann, Leszek Nosek, et al.
The Lancet. Diabetes & Endocrinology|January 26, 2019
Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trialInge B Halberg, Karsten Lyby, Karsten Wassermann, et al.
Clinical Pharmacokinetics|May 17, 2019
The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male SubjectsInge B Halberg, Karsten Lyby, Karsten Wassermann, et al.
Drugs & Aging|November 23, 2016
A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes MellitusTim Heise, Ulrike Hövelmann, Eric Zijlstra, et al.
Diabetes, Obesity & Metabolism|May 20, 2022
What is the value of faster acting prandial insulin? Focus on ultra rapid lisproTim Heise, Carolina Piras de Oliveira, Rattan Juneja, et al.
Diabetes Research and Clinical Practice|December 25, 2018
Concentrated insulins in current clinical practiceNanette C Schloot, Robert C Hood, Sheila M Corrigan, et al.
Clinical Drug Investigation|February 11, 2017
Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection RegionsUlrike Hövelmann, Tim Heise, Leszek Nosek, et al.
Clinical Drug Investigation|June 10, 2017
Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. SrinivasTim Heise, Ulrike Hövelmann, Leszek Nosek, et al.
Pageof 15

Showing results (51-60 of 150) with videos related to

Sort By:
Pageof 15
The Journal of Clinical Endocrinology and Metabolism|April 16, 2013
Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitusDavid Polidori, Sue Sha, Atalanta Ghosh, et al.
Journal of Diabetes Science and Technology|October 16, 2013
A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trialAndreas Liebl, Jaime Davidson, Henriette Mersebach, et al.
Expert Opinion on Drug Metabolism & Toxicology|June 19, 2015
Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargineTim Heise, Ulrike Hövelmann, Leszek Nosek, et al.
The Lancet. Diabetes & Endocrinology|January 26, 2019
Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trialInge B Halberg, Karsten Lyby, Karsten Wassermann, et al.
Clinical Pharmacokinetics|May 17, 2019
The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male SubjectsInge B Halberg, Karsten Lyby, Karsten Wassermann, et al.
Drugs & Aging|November 23, 2016
A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes MellitusTim Heise, Ulrike Hövelmann, Eric Zijlstra, et al.
Diabetes, Obesity & Metabolism|May 20, 2022
What is the value of faster acting prandial insulin? Focus on ultra rapid lisproTim Heise, Carolina Piras de Oliveira, Rattan Juneja, et al.
Diabetes Research and Clinical Practice|December 25, 2018
Concentrated insulins in current clinical practiceNanette C Schloot, Robert C Hood, Sheila M Corrigan, et al.
Clinical Drug Investigation|February 11, 2017
Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection RegionsUlrike Hövelmann, Tim Heise, Leszek Nosek, et al.
Clinical Drug Investigation|June 10, 2017
Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. SrinivasTim Heise, Ulrike Hövelmann, Leszek Nosek, et al.
Pageof 15